ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37798442

Therapeutic developments in pancreatic cancer.

Hu ZI and 1 other. Nat Rev Gastroenterol Hepatol, 2024. Cited by 375 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Therapeutic developments in pancreatic cancer. Papers, record 37798442. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37798442

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic developments in pancreatic cancer.
PubMed
Journal
Nat Rev Gastroenterol Hepatol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
375
iCite
Relative citation ratio, by iCite
48.18, provisional
iCite
Revised in PubMed
2026-10-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hu ZIZ Ian
2O'Reilly EMEileen Mhttps://orcid.org/0000-0002-8076-9199

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Pancreatic NeoplasmsMajor topic
Carcinoma, Pancreatic DuctalMajor topic
Humans
Immunotherapy
Forecasting

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50 CA257881NCI NIH HHSUnited StatesP50CA257881PubMed

Source NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07226154Prediction of Neoadjuvant Chemotherapy Response in Pancreatic CancerBackground

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References191

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,275,632Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.JAMA Surg2016https://conductscience.org/library/papers/27275632PubMed
231,134,896Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer.Elife2019https://conductscience.org/library/papers/31134896PubMed
334,644,529Spatially confined sub-tumor microenvironments in pancreatic cancer.Cell2021https://conductscience.org/library/papers/34644529PubMed
425,678,581Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Cancer Immunol Res2015https://conductscience.org/library/papers/25678581PubMed
532,135,080Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol2020https://conductscience.org/library/papers/32135080PubMed
632,931,022Clinical trial design: Past, present, and future in the context of big data and precision medicine.Cancer2020https://conductscience.org/library/papers/32931022PubMed
733,387,490
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol2021https://conductscience.org/library/papers/33387490PubMed
821,934,105An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.Oncologist2011https://conductscience.org/library/papers/21934105PubMed
936,459,568Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.Cancer Res2023https://conductscience.org/library/papers/36459568PubMed
108,097,319Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8097319PubMed

1 to 10 of 191

See all 191 references

Cited by277

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 375 citations.

PMIDTitleJournalYearIn PapersSource
42,983,487Dual-organelle-coordinated sonodynamic nanoplatform amplifies immunogenic cell death to drive robust antitumor immunity in cold tumors.J Nanobiotechnology2026https://conductscience.org/library/papers/42983487PubMed
42,952,609Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.Front Immunol2026https://conductscience.org/library/papers/42952609PubMed
42,934,594Burdens of pancreatic cancer from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study.BMC Cancer2026https://conductscience.org/library/papers/42934594PubMed
42,892,656Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells.Amino Acids2026https://conductscience.org/library/papers/42892656PubMed
42,873,463Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers.Curr Oncol Rep2026https://conductscience.org/library/papers/42873463PubMed
42,861,168Sialic Acid-Targeting Lectin-Conjugated Oxygen Nanosomes Alleviate Hypoxia and Promote Macrophage Activation in Pancreatic Cancer Cells.Int J Nanomedicine2026https://conductscience.org/library/papers/42861168PubMed
42,858,298MVB Maturation Responsive to KRASG12D/TP53R175H Co-mutations Fuels Extracellular Vesicle-hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis.J Extracell Vesicles2026https://conductscience.org/library/papers/42858298PubMed
42,856,962Super-Resolution MRI-Derived Tumor-Stroma Ratio Phenotyping for Prognostic and Therapeutic Stratification in Pancreatic Ductal Adenocarcinoma.MedComm (2020)2026https://conductscience.org/library/papers/42856962PubMed
42,844,287Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma.Nat Commun2026https://conductscience.org/library/papers/42844287PubMed
42,797,417Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797417PubMed

1 to 10 of 277

See all 277 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KRAS3,845PubTator's text mininghttps://conductscience.org/library/genes/3845

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37798442

GET https://conductscience.org/api/papers/v1/37798442/references?page=2

API referenceFor AI assistants